All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#ASH24: Hodgkin lymphoma
To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to Hodgkin lymphoma, here.
CONGRESS | #ASH24 | POSTER
— Lymphoma Hub (@lymphomahub) December 12, 2024
Bruce D. Cheson, Center for Cancer and Blood Disorders, shared long term data from a phase II trial of brentuximab vedotin and nivolumab in older (>60 yrs) patients with untreated Hodgkin #lymphoma.
At a median follow-up of 58.5 months, 58.7% of the… pic.twitter.com/Q3NtQOlvgV
CONGRESS | #ASH24 | Alison Moskowitz @MSKCancerCenter discusses the feasibility of pembrolizumab maintenance after pembro-GVD for R/R HL in CR. Overall 24-mo PFS 60%, stage I-III 24-mo PFS 72%, stage IV 24-mo PFS 37%. Pts with stage IV are more likely to require transplant.… pic.twitter.com/T6yWi2VyyQ
— Lymphoma Hub (@lymphomahub) December 9, 2024
CONGRESS | #ASH24 | Justin Ferdinandus @jusferdinandus @UKKoeln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS… pic.twitter.com/u3sN9YgHzg
— Lymphoma Hub (@lymphomahub) December 9, 2024
CONGRESS | #ASH24 | PRESENTATION@LisaRoth_MD @WeillCornell shares updated results from the phase II KEYNOTE-667 trial.
— Lymphoma Hub (@lymphomahub) December 9, 2024
After additional follow-up, pembrolizumab plus AVD consolidation, radiotherapy, and pembrolizumab maintenance demonstrated promising activity and a manageable… pic.twitter.com/lX0MUjRERb
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
